Management of Advanced-Phase Chronic Myelogenous Leukemia

被引：0
作者：
Radich, Jerald P. [1 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2016年 / 14卷 / 5.5期
关键词：
CHRONIC MYELOID-LEUKEMIA; FOLLOW-UP; IMATINIB; CML;
D O I：
10.6004/jnccn.2016.0188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chronic myelogenous leukemia represents the poster child of successful precision medicine in cancer, with amazing survival results achieved with targeted tyrosine kinase inhibitors (TKIs) in many patients with chronic-phase disease. Unfortunately, however, this good news has not extended to patients in blast crisis, for whom survival has not clearly been improved with TKIs. During his presentation at the NCCN 21st Annual Conference, Jerald P. Radich, MD, briefly explored the biology behind advanced-stage disease and several of the molecular findings in disease progression. He also reviewed some of the therapeutic options in advanced disease, emphasizing that transplantation, although fraught with some difficulties, offers the best long-term prognosis for patients in blast crisis.
引用
收藏
页码：669 / 671
页数：3
相关论文
共 8 条
  • [1] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Druker, Brian J.
    Guilhot, Francois
    O'Brien, Stephen G.
    Gathmann, Insa
    Kantarjian, Hagop
    Gattermann, Norbert
    Deininger, Michael W. N.
    Silver, Richard T.
    Goldman, John M.
    Stone, Richard M.
    Cervantes, Francisco
    Hochhaus, Andreas
    Powell, Bayard L.
    Gabrilove, Janice L.
    Rousselot, Philippe
    Reiffers, Josy
    Cornelissen, Jan J.
    Hughes, Timothy
    Agis, Hermine
    Fischer, Thomas
    Verhoef, Gregor
    Shepherd, John
    Saglio, Giuseppe
    Gratwohl, Alois
    Nielsen, Johan L.
    Radich, Jerald P.
    Simonsson, Bengt
    Taylor, Kerry
    Baccarani, Michele
    So, Charlene
    Letvak, Laurie
    Larson, Richard A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417
  • [2] A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression
    Giotopoulos, George
    van der Weyden, Louise
    Osaki, Hikari
    Rust, Alistair G.
    Gallipoli, Paolo
    Meduri, Eshwar
    Horton, Sarah J.
    Chan, Wai-In
    Foster, Donna
    Prinjha, Rab K.
    Pimanda, John E.
    Tenen, Daniel G.
    Vassiliou, George S.
    Koschmieder, Steffen
    Adams, David J.
    Huntly, Brian J. P.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (10) : 1551 - 1569
  • [3] A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
    Grossmann, V.
    Kohlmann, A.
    Zenger, M.
    Schindela, S.
    Eder, C.
    Weissmann, S.
    Schnittger, S.
    Kern, W.
    Mueller, M. C.
    Hochhaus, A.
    Haferlach, T.
    Haferlach, C.
    [J]. LEUKEMIA, 2011, 25 (03) : 557 - 560
  • [4] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Branford, Susan
    Mueller, Martin C.
    Kaeda, Jaspal S.
    Foroni, Letizia
    Druker, Brian J.
    Guilhot, Francois
    Larson, Richard A.
    O'Brien, Stephen G.
    Rudoltz, Marc S.
    Mone, Manisha
    Wehrle, Elisabeth
    Modur, Vijay
    Goldman, John M.
    Radich, Jerald P.
    [J]. BLOOD, 2010, 116 (19) : 3758 - 3765
  • [5] Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Saglio, Giuseppe
    Luis Steegmann, Juan
    Shah, Neil P.
    Boque, Concepcion
    Chuah, Charles
    Pavlovsky, Carolina
    Mayer, Jiri
    Cortes, Jorge
    Baccarani, Michele
    Kim, Dong-Wook
    Bradley-Garelik, M. Brigid
    Mohamed, Hesham
    Wildgust, Mark
    Hochhaus, Andreas
    [J]. BLOOD, 2014, 123 (04) : 494 - 500
  • [6] Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    Abruzzo, Lynne
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Champlin, Richard
    Pierce, Sherry
    Alattar, Mona Lisa
    Trinh, Long Xuan
    Luthra, Raja
    Ferrajoli, Alessandra
    Kadia, Tapan
    O'Brien, Susan
    Cortes, Jorge E.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (02) : 155 - 162
  • [7] First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
    Rea, D.
    Etienne, G.
    Nicolini, F.
    Cony-Makhoul, P.
    Johnson-Ansah, H.
    Legros, L.
    Huguet, F.
    Tulliez, M.
    Gardembas, M.
    Bouabdallah, K.
    Rousselot, P.
    Cayuela, J-M
    Guilhot, F.
    Mahon, F-X
    [J]. LEUKEMIA, 2012, 26 (10) : 2254 - 2259
  • [8] Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
    Saussele, Susanne
    Lauseker, Michael
    Gratwohl, Alois
    Beelen, Dietrich W.
    Bunjes, Donald
    Schwerdtfeger, Rainer
    Kolb, Hans-Jochem
    Ho, Anthony D.
    Falge, Christiane
    Holler, Ernst
    Schlimok, Guenter
    Zander, Axel R.
    Arnold, Renate
    Kanz, Lothar
    Dengler, Robert
    Haferlach, Claudia
    Schlegelberger, Brigitte
    Pfirrmann, Markus
    Mueller, Martin C.
    Schnittger, Susanne
    Leitner, Armin
    Pletsch, Nadine
    Hochhaus, Andreas
    Hasford, Joerg
    Hehlmann, Ruediger
    [J]. BLOOD, 2010, 115 (10) : 1880 - 1885
1